Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Next Previous
X
Search
Trial Profile

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danicamtiv (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; Proof of concept
  • Sponsors MyoKardia

    • Most Recent Events

    • 22 Jun 2020 According to a MyoKardia media release, the company will host a conference call and webcast for investors and analysts today to review the data from this study and to discuss future development plans for danicamtiv in targeted groups of patients with systolic disease.
    • 22 Jun 2020 According to a MyoKardia media release, positive phase 2a results were published in the European Journal of Heart Failure.
    • 22 Jun 2020 According to a MyoKardia media release, positive phase 2a results were featured in a Late-Breaking Science Session during the HFA Discoveries online event from the Heart Failure Association of the European Society of Cardiology (ESC).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top